Condition: Resectable Hepatocellular Carcinoma · Sponsor: Fujian Provincial Hospital
This study is a single-arm, multi-center, prospective phase II trial aimed at evaluating the efficacy and safety of neoadjuvant therapy with transarterial chemoembolization (TACE) combined with lenvatinib and camrelizumab (triple therapy) in patients with resectable hepatocellular carcinoma (HCC). The study plans to enroll 20 patients. The primary endpoints are major pathological response (MPR) rate and safety, while the secondary endpoints are recurrence-free survival (RFS), objective response rate (ORR), R0 resection rate, and overall survival (OS).
This description comes directly from the study's public registry record.
Mao-Lin Yan · 0591-88217140 · yanmaolin74@163.com
Always discuss trial participation with your own doctor first.
| Fujian provincial hospital | Fuzhou, Fujian, China | Recruiting |
| First Affiliated Hospital of Fujian Medical University | Fuzhou, Fujian, China | Not Yet Recruiting |
| Mengchao Hepatobiliary Hospital of Fujian Medical University | Fuzhou, Fujian, China | Not Yet Recruiting |
| Zhongshan Hospital of Xiamen University | Xiamen, Fujian, China | Not Yet Recruiting |
| First Affiliated Hospital of Xiamen University | Xiamen, Fujian, China | Not Yet Recruiting |
| Zhangzhou Affiliated Hospital of Fujian Medical University | Zhangzhou, Fujian, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06569498